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Abstract
Background: Nucleofection is an emerging technology for delivery of nucleic acids into both the
cytoplasm and nucleus of eukaryotic cells with high efficiency. This makes it an ideal technology for
gene delivery and siRNA applications. A 96-well format has recently been made available for high-
throughput nucleofection, however conditions must be optimized for delivery into each specific cell
type. Screening each 96-well plate can be expensive, and descriptions of methods and outcomes to
determine the best conditions are lacking in the literature. Here we employ simple methods,
including cell counting, microscopy, viability and cytotoxicity assays to describe the minimal
experimental methods required to optimize nucleofection conditions for a given cell line.
Methods: We comprehensively measured and analyzed the outcomes of the 96-well nucleofection
of pmaxGFP plasmids encoding green fluorescent protein (GFP) into the A-549 human lung
epithelial cell line. Fluorescent microscopy and a plate reader were used to respectively observe
and quantify green fluorescence in both whole and lysed cells. Cell viability was determined by
direct counting/permeability assays, and by both absorbance and fluorescence-based plate reader
cytotoxicity assays. Finally, an optimal nucleofection condition was used to deliver siRNA and gene
specific knock-down was demonstrated.
Results: GFP fluorescence among conditions ranged from non-existent to bright, based upon the
fluorescent microscopy and plate reader results. Correlation between direct counting of cells and
plate-based cytotoxicity assays were from R = .81 to R = .88, depending on the assay. Correlation
between the GFP fluorescence of lysed and unlysed cells was high, ranging from R = .91 to R = .97.
F i n a l l y ,  d e l i v e r y  o f  a  p o o l e d  s a m p l e  o f  s i R N A s  t a r g e t i n g  t h e  g e n e  r e l A  u s i n g  a n  o p t i m i z e d
nucleofection condition resulted in a 70–95% knock down of the gene over 48 h with 90–97% cell
viability.
Conclusion: Our results show the optimal 96-well nucleofection conditions for the widely-used
human cell line, A-549. We describe simple, effective methods for determining optimal conditions
with high confidence, providing a useful road map for other laboratories planning optimization of
specific cell lines or primary cells. Our analysis of outcomes suggests the need to only measure
unlysed, whole-cell fluorescence and cell metabolic activity using a plate reader cytotoxicity assay
to determine the best conditions for 96-well nucleofection.
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Background
The transfection of molecules into mammalian cells is an
essential tool for the study of gene function, the delivery
of genetic therapy agents, and for cell diagnostics and
imaging. Many different transfection methods have been
developed, including chemical (reviewed in [1]), 'biolis-
tic' or ballistic bombardment [2], viral [3], electropora-
tion [4,5], microinjection, and liposomal[6] delivery
technologies. Most of these approaches are limited by low
transfection efficiencies, high cytotoxicity, and the inabil-
ity to deliver nucleic acid past the nuclear barrier within
the cell, especially in primary cell lines.
Nucleofection is an emerging technology for intracellular
molecular delivery. It is typically used in a single-cuvette
format for delivery of nucleic acids such as plasmids and
siRNA, and has been successfully used to deliver nucleic
acids into human embryonic stem cells, adult stem cells,
myoblasts, monocytes, human keratinocytes, murine
stem cells, and many others [7-14]. A non-viral delivery
system, it has shown promise in the successful transfec-
tion of normally hard to transfect cells [9], however, it
could also potentially be used to deliver proteins, inor-
ganic compounds, nanoparticles, drugs, and toxins. Char-
acteristic of nucleofection is its ability to deliver molecules
into the nucleus as well as the cytoplasm, which offers a
distinct advantage over non-viral delivery strategies that
generally only deliver into the cytoplasm [15,16].
Nucleofection is achieved by combining low voltage elec-
troporation with one of several reagents to allow the effi-
cient transfer of nucleic acids into cells while minimizing
toxicity [17,18]. The reagents are proprietary in nature,
but generally consist of a combination of modular protein
complexes that combine with charged particles such as
nucleic acids, forming a nucleoprotein complex [19]. Dif-
ferent protein complexes facilitate separate functions,
such as cell membrane association, translocation, endo-
somal release, and nuclear transport [19]. The entire pro-
cedure has been optimized in the single-cuvette format for
a variety of mammalian cell types, and recently for a 96-
well shuttle system. However, the shuttle system must be
optimized for each cell type, which involves the screening
of up to 96 conditions to select the best one for efficient
nucleofection. The parametric conditions are a combina-
tion of three proprietary reagents and 31 different electri-
cal pulse-shaping options. The reagents are expensive,
costing several hundred dollars per plate, while descrip-
tions of the methods/outcomes for the 96 conditions and
easy-to-use protocols for the evaluation of the results are
lacking. We therefore performed several simple, duplicate
assays, and then compared their outcomes to determine
the simplest, most cost-effective requirements to optimize
any given cell line. The techniques we evaluate here
include fluorescence microscopy, a fluorescence plate
reader, cell permeability assays/direct cell counting, and
both absorbance- and fluorescence-based cytotoxicity
assays. In addition, we specifically discuss the optimal
nucleofection conditions for a human epithelial cell line:
A549, and recommend the minimal assays needed for
evaluating optimal delivery conditions and delivery out-
comes using this shuttle system. The results described here
will serve as a useful reference for others wanting to opti-
mize the 96-well shuttle system for any cell line.
Methods
Initial Nucleofection Optimization
Nucleofection was carried out using the Cell Line Optimi-
zation 96-well Nucleofector Kit from Amaxa http://
www.amaxa.com according to the manufacturer's recom-
mendations. Briefly, A549 cells (ATCC – Manassas, VA)
were grown to 85% confluency in complete media (Dul-
becco's Modified Eagle's Medium (DMEM) (Cellgro-
Herndon, Virginia), supplemented with 10% (v/v) fetal
calf serum (HyClone – Logan, Utah), 1% (v/v) penicillin,
1% (v/v) streptomycin (Sigma – St. Louis, Missouri)) and
detached from culture flasks using trypsin (Cellgro).
Complete media was added and the cells were split into
three aliquots each containing approximately 8.75 × 106
cells. The aliquots were centrifuged at 800 rpm for 10
minutes and the media was completely removed from the
pellet. Each of the three cell pellets was re-suspended in
the three different nucleofection solutions (SE, SF, and
SG) and 12.8 μg pMAX GFP plasmid was added to each
solution. Each well in the 96-well nucleofection plate was
loaded with 20 μL of one of the three nucleofection solu-
tions (approximately 275,000 cells) and the plate was
loaded into the Amaxa 96-well Shuttle for nucleofection.
Upon completion of the nucleofection program and after
a 10 minute incubation period, 80 μL of pre-warmed
complete media was added to each well of the 96-well
Nucleocuvette plate giving 100 μL total volume in each
well. For recovery plates, two identical 96-well, flat-bot-
tom plates, and 1 clear-bottomed/opaque walled 96-well
plate (Becton-Dickenson) were then prepared by adding
25 μL of each nucleofected well to 175 μL of pre-warmed
media. The opaque walled plate was used for a subse-
quent fluorescent assay measuring cell metabolic activity,
in order to prevent any interference of fluorescence from
neighbouring wells. In this way, each nucleofection con-
dition had three identical growing conditions in the
recovery plates. The cells were then incubated for 24–48 h
in a humidified 37°C/5% CO2 atmosphere, and then
used for either microscopy + fluorescence plate reading,
absorbance or fluorescence cytotoxicity assay, or cell
counting/Trypan Blue viability assay.
Secondary Nucleofection Optimization
A second nucleofection optimization was performed
using SE reagent, which allowed the further evaluation ofGenetic Vaccines and Therapy 2009, 7:6 http://www.gvt-journal.com/content/7/1/6
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this reagent in triplicate under all 32 nucleofection condi-
tions. This optimization was performed as described
above, but with the SE reagent substituted for the SF and
SG reagents.
Microscopy and GFP fluorescence detection
After 24 hrs, the cells in the clear-bottom, opaque-walled
recovery plate were analyzed by both bright-field and flu-
orescence microscopy with a 20× objective using an
Olympus microscope. For the GFP excitation, an Argon
laser was used with λexe = 488 nm. After microscopy,
quantitative measurement of GFP/well was performed in
two ways: first by direct measurement of whole-cell GFP
in each well, and secondly by lysis of cells to release GFP
in order to yield a more homogeneous measurement. Cell
lysis was induced by the addition of 5 uL of 0.2 N HCl,
and the fluorescence measured immediately after lysis.
The GFP fluorescence was measured each time with a
Tecan plate reader using λexe = 485, λem = 525 nm.
Cell Number and Viability Determination
The actual cell number and viability was determined using
a standard Trypan-Blue membrane permeability assay, in
which all cells from each well in one of the non-opaque
walled recovery plates were counted on a hematocytome-
ter. In order to account for dead and dying cells that may
have become detached, plates were centrifuged for 10
minutes at 800 rpm and the media was removed. The
plate was then washed once with 1× DPBS, trypsinized,
and complete media was added. The live and dead cells
were then stained with trypan blue, counted, and percent
viability was calculated as the number of live cells/total
number of cells × 100.
Toxicity Assays
The initial nucleofection optimization was evaluated
using only GFP fluorescence, microscopy, and absolute
cell number. For further evaluation and to alleviate the
need for classical cell counting, the viability and cytotox-
icity of cells from the SE optimization were analyzed using
two different commercially available kits. First, the Cell-
titer 96 Aqueous One Solution Cell Proliferation Assay
(Promega) measures live cell metabolic activity (live cell
absorbance assay). Briefly, the presence of live cells is
measured colorimetrically by the reduction of a tetrazo-
lium salt substrate into a formazan product. NADPH pro-
vides the reducing power to catalyze the formazan
conversion, resulting in a linear relationship between the
amount of formazan produced, and the number of cells
present. The formazan product in this assay is soluble, and
can be detected using simple absorbance. The second
assay used in this assessment was the MultiTox-Fluor Mul-
tiplex Cytotoxicity Assay (Promega), which is intended to
measure live/dead cells simultaneously (live cell fluores-
cence assay). In this assay, a reagent containing both the
live and dead cell indicators is used. The live cell indicator
consists of a proprietary peptide substrate conjugated to a
glycyl-phenylalanyl-amino-fluorocumarin (GF-AFC),
which is permeable to the cell membrane. Entry into the
cell membrane results in peptide cleavage by live cell pro-
teases, and detection at 505 nm via excitation at 400 nm.
The dead cell indicator is likewise a cell impermeable pep-
tide substrate conjugated to a bis-alanyl-alanyl-phenylala-
nyl-rhodamine 110 (bis-AAF-R110), whose
spectrophotometric properties are activated upon peptide
cleavage (excitation at 485 nm/emission at 520 nm) How-
ever, for our comparisons, we only evaluated the use of
the live cell, GF-AFC assay so it could be correlated to
direct cell counting and metabolic activity measured by
MTS. For each assay, cells were nucleofected and then
allowed to proliferate for 48 hours before addition of the
tetrazolium salt (AqueousOne), or the Live (GF-AFC) rea-
gent of the MultiTox assay. Cells were then assayed
according to the manufacturer's specifications for each kit.
Data Bioinformatics
To determine the optimal nucleofection conditions, we
converted the raw data obtained from the secondary opti-
mization to a standardized form, clustered the standard-
ized data, and generated a heat map. The heat map allows
many data sets to be clustered, visualized, and compared
with each other in order to determine the best conditions.
Briefly, each data point was first standardized by subtract-
ing the mean of the data set from each data point and then
dividing by the standard deviation of the data set. Stand-
ardized and raw data for the secondary optimization can
be viewed in the supplementary file [see Additional file 1].
Heat maps were then generated using dChip2005 http://
www.hsph.harvard.edu/~cli/complab/dchip/, which uses
hierarchical clustering to compare and group the data sets
that have the highest degree of similarity. For the correla-
tions (Table 1), the 3 trials were averaged and the r values
were obtained using linear regression.
siRNA delivery and qPCR
ON-TARGETplus SMARTpool siRNA constructs were pur-
chased from Dharmacon Inc (Lafayette, CO) for rel-A (L-
003533-00-0005). The siRNA preparations were re-sus-
pended in 1× siRNA buffer (20 mM KCl, 6 mM HEPES-pH
Table 1: Data correlation statistics from the secondary 
nucleofection optimization
Correlations R value
Total Live Cells 24 hr. vs. Absorbance Assay 24 hr .81
Total Live Cells 24 hr. vs. Fluorescence Assay 24 hr .88
Absorbance Assay 24 hr vs. Fluorescence Assay 24 hr .79
GFP (non-lysed) 24 hr vs. GFP (lysed) 24 hr .91
GFP (non-lysed) 48 hr vs. GFP (lysed) 48 hr .97
Absorbance Assay 48 hr vs. Fluorescence Assay 48 hr .56Genetic Vaccines and Therapy 2009, 7:6 http://www.gvt-journal.com/content/7/1/6
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7.5, 0.2 mM MgCl2) to working concentrations of 20 μM,
and then delivered at concentrations of 0 nM (only 1×
siRNA buffer), 100 nM, 250 nM, or 500 nM concentra-
tions in the 96-well format using the nucleofector shuttle
system. From the conditions determined in the optimiza-
tion described below, each well contained 2.75 × 105 cells
in Amaxa cell line solution SE, using program code 96-
DS:150, and the standard control option. Transfected cells
were split into 4 plates for recovery, resulting in 7 × 104
cells/well. Cells were counted and collected at 24 and 48
h following siRNA delivery by re-suspension in Cells-to-
Signal lysis buffer (Applied Biosystems/Ambion, Austin,
Texas, USA), and then qPCR was performed using a lysate
equivalent to 100 cells/qPCR reaction. Real-time, quanti-
tative PCR (qPCR) was performed according to the manu-
facturer's specifications using Taqman primer/probe sets
purchased from Applied Biosystems, Inc (Foster City, Cal-
ifornia, USA) for Rel A (Primer set ID: Hs00153294_m1).
Results
Optimization Strategy
To determine the optimal condition for nucleofection of
the A-549 epithelial cell line, an initial optimization
experiment was performed as described by the manufac-
turer. Cell/nucleic acid mixtures were combined with one
of the 3 proprietary reagents: SE, SF, and SG, such that
each reagent/cell/nucleic acid mixture occupies 1/3 of the
96-well electroporation plate. In each 1/3 of the plate, the
cell/nucleic acid/reagent mixture is exposed to one of 31
different electric pulses, and 1 no-pulse control. In this
way 96 conditions can be evaluated on a single plate, in
which each well represents a different condition. Perform-
ing an optimization experiment in this way allows the
evaluation of 96 different conditions; however since each
well is represented only once, statistical reliability is
absent. Repeating the optimization with the same 96-well
conditions can be costly, and still not provide an appro-
priate biological replication in an individual experiment.
We, therefore, used the initial optimization experiment as
a 'screen' to pick the most promising reagent. Compre-
hensive data from this primary optimization can be
observed in the supplementary file [see Additional file 1].
Following this, a secondary optimization was run using
the best reagent in triplicate on a single 96-well plate. In
this way, promising conditions were both repeated and
biologically replicated.
To characterize the range of possible outcomes for the 96
nuclefection conditions, we monitored GFP levels and cell
viability, via microscopy, plate reader, and trypan blue
counting. Microscopy of the 96-well initial primary opti-
mization (screen) is shown in Figure 1A. Most of the wells
had some degree of successful nucleofection of the GFP
plasmid shown by a homogeneous expression of green
fluorescence. The electrical pulse patterns also show con-
sistency among the 3 different reagents and their resulting
GFP expression in each well. Bright-field microscopy was
also performed on each well in the 96-well screen, with
many wells exhibiting both good cell morphology and
good GFP expression (data not shown). Fluorescence
from GFP was measured using a plate reader on both lysed
and non-lysed cells. Cell lysis was performed in order to
release and homogenize GFP fluorescence throughout the
well and mitigate any non-homogeneous cell coverage or
instrument detection per well. Green fluorescence read-
ings from both lysed and non-lysed cells were compared
to determine any differences in outcome between meth-
ods and good correlation was found between the two
methods (r = 0.95). Overall, fluorescence microscopy and
plate reader signals ranged from completely absent to
highly fluorescent and cell viability ranged from 72 to
100%. Total live cell number ranged from 6,000 to
193,000, with some wells showing massive cell loss fol-
lowing nucleofection.
As expected, an inverse relationship was observed
between GFP fluorescence and cell viability. Therefore, we
needed to determine the nucleofection conditions that
can simultaneously provide moderate live cell number,
high GFP fluorescence and nominal cell integrity as deter-
mined by microscopy. Based upon the fluorescence
microscope images in Figure 1A and 1C and the analysis
of a heat map containing all the results in a standardized
form (data not shown), it was determined that the condi-
tions used in well G2 (Reagent SE, program 96-DS:150)
yielded cells with the best combination of results: the
maximum GFP fluorescence, a total live cell count of
80,000 cells which falls above the median (68,500), nom-
inal cell morphology, and high fluorescence under the
microscope.
Secondary Optimization
In order to confirm the initial screening, observe any var-
iation, and evaluate the most promising conditions, a sec-
ond optimization was performed using the reagent with
the best transfection characteristics determined from the
screen. Based on the GFP microscopy and fluorescence
and the live cell numbers from the initial optimization,
reagent SE gave the best overall results of any reagent, and
was therefore used in the secondary optimization. The
results of the secondary SE optimization are shown in the
microscopy images in Figure 1B, the Secondary Optimiza-
tion data in the supplementary file [see Additional file 1],
and the heat map in Figure 2 which allows data to be eas-
ily compared and the best wells/conditions to be deter-
mined. Similar results were observed, with fluorescence
ranging from completely absent to highly fluorescent and
cell viability ranging from 68% to 100%. Total live cell
number ranged from 1,500 to 134,000, with some wells
showing massive cell loss following nucleofection. TheGenetic Vaccines and Therapy 2009, 7:6 http://www.gvt-journal.com/content/7/1/6
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optimal condition determined from the secondary nucle-
ofection is in well H2 (Figure 1C) which showed high GFP
fluorescence, nominal morphology via microscopy, and a
moderate live cell number of 73,000 which falls above the
median (45,500). Interestingly, the optimal well deter-
mined here differed from that determined in the initial
nucleofection, illustrating the utility of a second optimiza-
tion.
In general, the variation among the three trials in each
condition was large [see Additional file 1]. Even though
conditions were averaged to increase reliability, it is worth
noting that, in what appear to be identical replicates,
moderate differences can be expected in nucleofection
efficiencies, an important consideration in downstream
experiments.
Minimal Evaluation Assay Determination
To determine the simplest assays needed to find the opti-
mal condition, we directly compared results for each
assay. Comparing both the clustering hierarchy in the heat
map (Figure 2), and the correlation values between redun-
dant assays (Table 1), we determined that only a few
measurements are needed to evaluate any given 96-well
shuttle nucleofection experiment. The lysed vs. non-lysed
GFP from both 24 and 48 hr correlate closely, which indi-
cates that the GFP can be reliably measured on the 96-well
plate without the addition of a lysis reagent. In addition,
Fluorescence microscopy of nucleofection optimizations Figure 1
Fluorescence microscopy of nucleofection optimizations. (A) Microscopy images of the initial nucleofection optimiza-
tion. Each well was subjected to a particular proprietary electroporation condition, designated by the serial number overlaid 
on each picture, and preceded by the number 96-(For example: Well B2 corresponds to 96-EH-100). Wells in columns 1–4 
represent 32 different electroporation conditions, evaluating cells nucleofected in proprietary reagent SE. Columns 5–8 repeat 
the same 32 electroporation conditions in proprietary reagent SF, while columns 9–12 evaluate the 32 conditions in reagent 
SG. Wells H4, H8, and H12 are controls that contained the respective nucleofection reagents, but were not electroporated. 
(B) Microscopy of the secondary optimization containing SE only. Microscopy is only shown for 1/3 of the plate, representing 
each unique electroporation condition. Well H4 is the control well which was not electroporated. (C) Well G2 from initial 
optimization and H2 from SE optimization showing GFP throughout the cells.Genetic Vaccines and Therapy 2009, 7:6 http://www.gvt-journal.com/content/7/1/6
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the total live cell number correlates well with both the
absorbance cell viability assay and the fluorescence cell
viability assay at 24 hr. The correlation is less clear at 48
hr, possibly due to different maximum limits of detection
between the assays. In fact, for the secondary optimiza-
tion, each individual assay agrees on the same optimal
well condition (H2). This suggests that one need only
measure non-lysed GFP fluorescence (using a plate
reader) and cell viability by a simple assay (either the
absorbance or fluorescence based) to evaluate the effects
of a given condition/cell line for nucleofection.
Delivery of siRNA and observable knock down of targeted 
genes
Finally, to demonstrate efficient knockdown, we used one
of the optimized conditions to deliver siRNA constructs
using nucleofection with the aim of knocking down
expression of human rel-a (NM_021975). The siRNA
preparation consisted of a pooled sample of 4 sense, and
4 antisense sequences corresponding to 4 different
regions of the target gene. The pooling of low concentra-
tions of the 4 different sense/antisense pairs into 1 sample
allows for a combinatorial targeting of the gene and limits
off-target effects brought on by using higher concentra-
tions of just a single pair. In addition, siRNAs are chemi-
cally modified to inhibit other off target affects, such as
those caused by unfavourable RISC interaction of the seed
strand, and anti-sense strand-related off-targeting induced
by similar 3'UTR seeds [20,21]. Figure 3 shows the knock-
down as measured by qPCR at 24 and 48 h for rel A over
several concentrations delivered. In all cases, the tran-
scripts were consistently knocked down to levels 70–95%
lower than that detected in the controls.
Discussion
Following an initial screening, we picked the SE reagent as
the best choice to continue with a secondary optimiza-
tion, although one could also pick combinations of the
best wells from other reagents and evaluate them in tripli-
cate under similar conditions. The use of a heat map to
compare GFP and cell viability side by side is useful for
determining the best conditions for nucleofection (Figure
2). For example, high GFP (and therefore high GFP/cell)
would not necessarily be the best condition due to low
total cell survival. The use of the heat map shows that well
H2 yields the best combination of high GFP and viability.
Conditions that yield large negative correlations between
GFP fluorescence and cell number can also be compared
and screened, and excessive cell deaths due to condition-
related toxicity can be readily observed, such as cell death
caused by lethal amounts of calcium-influx from electro-
poration-mediated holes in the membrane.
Certain assays are nominal for evaluating optimization,
and do not require further refinement. For example, the
linear, highly correlated relationship that exists between
measurements of lysed and non-lysed GFP, as well as
between trypan-blue counting and different cell viability
assays. That is, one needs only to measure GFP fluores-
cence in intact cells, and perform a simple commercial 96-
well cell viability assay to get reliable data. Therefore, the
use of the screen plus secondary optimization, in conjunc-
tion with one of the fluorescence and cytotoxicity assays
Heat map of data from the secondary SE optimization Figure 2
Heat map of data from the secondary SE optimization. Data has been standardized, with colors indicating high and low 
values. As seen on the scale, red indicates a high value relative to the mean of the individual data set, while green indicates a 
low value relative to the mean of the individual data set. Well H2 represents the best combination of GFP fluororescence, cell 
number, and cell viability.Genetic Vaccines and Therapy 2009, 7:6 http://www.gvt-journal.com/content/7/1/6
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used here, can help determine the best balance of delivery
and cell survival.
We have also used the delivery of siRNA pooled samples
targeting rel A as a test platform to assay this optimized
format for A-549 cells and shown the successful knock-
down of rel A in a time- and concentration-dependent
manner. The effective siRNA concentration range that we
observe here is typical of standard concentrations used for
single gene knockouts recommended by the manufacturer
(250 nM-500 nM) as well as for genomic or pathway
multi-gene knockdown screening (100 nM). Despite the
success of delivery and the observable transcript pheno-
type, we did not optimize the nucleofection system here
for siRNA delivery, but only for pmaxGFP plasmid deliv-
ery. Therefore, better conditions might exist to achieve a
higher and more sustained knock down using this system.
Conclusion
The introduction of the 96-well nucleofection shuttle sys-
tem facilitates powerful gene delivery applications, allow-
ing large numbers of conditions and replicates to be
performed, and will find uses in high throughput screen-
ing, systematic knockdown studies, and even for ex vivo
gene therapy applications. It is easy to use, attaining high
transfection efficiencies and homogeneous intercellular
distribution of the delivered nucleic acid within both the
cytoplasm and the nuclear barrier. Therefore, siRNA deliv-
ery will also likely penetrate the nuclear envelope, leading
to a more sustained knock-down. Optimization using this
methodology can be carried out to determine the best
conditions for each cell line so as to mitigate cell deaths
and cell-proliferation inhibition, and to increase efficient
transfection conditions. However, investigators should be
aware of variations in individual replicates and take steps
to mitigate their effects on outcomes, such as nucleic acid
delivery and cell viability. In summary, we were able to
optimize nucleofection conditions for A549 cells, define
the minimal assays needed for the evaluation of 96-well
shuttle results, and deliver an siRNA targeting complex
through nucleofection in a 96-well format. The methods
and results described here are widely applicable to those
wanting to implement this technology for use in any cell
line.
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